Premium
Synergic in vitro effects of interleukin‐2 and τ‐interferon on the migration of blood monocytes from control subjects and patients with lung cancer
Author(s) -
Vaillant Pierre,
Martinet Nadine,
Martinet Yves
Publication year - 1993
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/1097-0142(19931001)72:7<2141::aid-cncr2820720713>3.0.co;2-d
Subject(s) - medicine , lung cancer , monocyte , cancer , immunology , chemotaxis , in vivo , whole blood , in vitro , cancer research , biology , receptor , biochemistry , microbiology and biotechnology
Background . Macrophages can play a major role against cancer by exerting their cytotoxic activity against tumor cells. The presence of macrophages in tumor stroma is related to the recruitment of circulating blood monocytes through the release of chemotactic factors by cancer cells. However, fewer blood monocytes from patients with cancer, such as lung cancer, migrate from in vivo and in vitro, compared with blood monocytes control subjects. Methods . Two cytokines, interleukin‐2 (IL‐2) and τ‐interferon (τ‐INF), proposed in the treatment of cancer, were tested for their ability to modulate the migratory response in modified Boyden chemotactic chambers of blood monocytes obtained from control subjects and patients with lung cancer in the presence of two chemotactic factors: N‐formylmethionyl‐leucyl‐phenylalamine and complement fraction C5a (C5a). Results . Incubation with IL‐2 and τ‐INF resulted in a dose‐dependent depression of the migration of blood monocytes from control subjects and patients with lung cancer. IL‐2 depression was induced by IL‐2 concentrations of 10 5 units/ml, and τ‐IFN effects were measured for concentrations of 100 μ/ml. Furthermore, when low concentrations of IL‐2 were tested in combination with low concentrations of τ‐IFN, dose‐dependent depression of blood monocyte migration occurred. Conclusions . Dose‐dependent depression of blood monocyte migration may modulate the inflammatory component of tumor stroma in patients with lung cancer treated with these cytokines. It may also explain, in part, the high incidence of infections in patients treated with IL‐2.